Therapeutic Proteins Market Dominated by Roche, Amgen and Novo Nordisk: companiesandmarkets.com

LONDON--(BUSINESS WIRE)-- Valued at $93 billion in 2010, the therapeutic proteins market is expected to grow at a steady pace, according to a new report available on companiesandmarkets.com. Analysts anticipate a growth rate of 6.2% CAGR to 2017, at which point the market’s estimated worth will be $141.5 billion.

Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market

http://www.companiesandmarkets.com/Market-Report/therapeutic-proteins-market-to-2017-high-demand-for-monoclonal-antibodies-will-drive-the-market-686525.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

Facing strong competition from gene therapy and biogenerics, the market for protein therapeutics is likely to expand at a steady pace, although it is widely expected that the launch of orally administered treatments will encourage growth.

The monoclonal antibodies segment is likely to retain its position as the highest value portion of the market for the duration of the reporting period within this report, which also analyses interferons, blood factors, human growth hormone, erythropoietins, insulin and colony stimulating factors.

A number of therapeutic protein patent expirations have allowed pharmaceutical companies to develop their own generic alternatives, helping to fuel market growth.

The market is dominated by three companies – Roche, Amgen and Novo Nordisk – whose blockbuster drugs have netted them a combined share of over $50 billion of the $93 billion market. Despite this stronghold there are still a large number of smaller pharmaceutical companies competing within the sector, and new entrants are likely.

Several pipeline proteins are showing great potential, including: rhGAD65 (Diamyd); DiaPep277; Otelixizumab; Oral-Lyn; NecLip-pdFVIII; OBI-1; NN7008; Long Acting rFactor VIII; Human-cl rhFVIII; Abthrax (raxibacumab) and Simponi (golimumab).

The September 2011 publication contains 142 pages of analysis of the therapeutic proteins market, including historical and forecast data for the period 2010-2017. Geographic markets analysed within the report are: Europe (France, Germany, Italy, Spain and UK), Japan and the US. The report considers the drivers and obstacles of market growth and development, as well as the competitive landscape of the therapeutic proteins industry.

Profiles are provided for the following key pharmaceutical companies: Pfizer, Johnson & Johnson, Hoffmann-La Roche Ltd, Merck & Co., Inc, Eli Lilly and Company, Abbott Laboratories, Sanofi, Novo Nordisk, Amgen and Biogen.

Report Details:

http://www.companiesandmarkets.com/Market-Report/therapeutic-proteins-market-to-2017-high-demand-for-monoclonal-antibodies-will-drive-the-market-686525.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Paul Chapman
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.